CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 2 enrolled
Drug / intervention
rAAVrh74.MCK.GALGT2biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03333590
NCT03333590Phase 2Completed
CompareCT.gov

Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2

Kevin Flanigan·interventional·Posted Nov 7, 2017·Updated Mar 13, 2025

In Brief

A Phase 2 clinical trial evaluating rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy. Completed, enrolled 2 participants across 1 site.

Detailed Summary

The proposed clinical trial study of rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy (DMD) patients. There will be a modified intravascular limb infusion (ILI) procedure that will be used to sequentially deliver vector to each whole lower limb of DMD subjects via a major lower limb artery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuchenne Muscular Dystrophy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedNov 7, 2017
Enrollment StartNov 6, 2017
Primary CompletionNov 4, 2020
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.7 years ago

Interventions

rAAVrh74.MCK.GALGT2biological

Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)